GILD vs AMGN

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 19. 8x versus Amgen Inc. at 23. 1x. On forward P/E, Amgen Inc. is actually cheaper at 14. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to +46. 2% for Amgen Inc. (AMGN). Over 10 years, the gap is even starker: AMGN returned +156. 4% versus GILD's +87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Gilead Sciences, Inc. 's 0. 66β — meaning GILD is approximately 9% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Gilead Sciences, Inc. (GILD) carries a lower debt/equity ratio of 109% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 88. 2% for Amgen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 21. 0% for Amgen Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus 29. 1% for AMGN. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amgen Inc.

(AMGN) trades at 14. 7x forward P/E versus 15. 7x for Gilead Sciences, Inc. — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 20. 8% to $161. 88.

All stocks in this comparison pay dividends.

Amgen Inc. (AMGN) offers the highest yield at 2. 9%, versus 2. 4% for Gilead Sciences, Inc. (GILD).

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Both have compounded well over 10 years (AMGN: +156. 4%, GILD: +87. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.